Results from Vaccine Efficacy Trials, collected by Paul Tupper, Magpie Group, Simon Fraser University

please contact pft3@sfu.ca for corrections/additions

symptomatic infection

"documented infection"

asymptomatic infection

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

https://www.nejm.org/doi/full/10.1056/NEJMoa2035389

>=14 days after second dose

94.1% (95% CI, 89.3 to 96.8%

Note - symptomatic infection only I think

big Moderna result

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

https://www.nejm.org/doi/full/10.1056/NEJMoa2034577

>=7 days after second dose, no evidence of prior infection

doses 21 days apart

>=7 days after second dose, with our without evidence of prior infection

88.9% (95% CI, 20.1 to 99.7) see bottom of https://www.nejm.org/doi/10.1056/NEJMc2036242

between first and second dose

52% (95% CI, 29.5 to 68.4)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

https://www.nejm.org/doi/10.1056/NEJMc2036242

>=2 weeks after first dose, and before second dose

Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in the UK: a test negative case control study

https://khub.net/documents/135939561/430986542/Early%20effectiveness%20of%20COVID%20vaccines.pdf/ffd7161c-b255-8e88-c2dc-88979fc2cc1b?t=1614617945615

1st dose, adults 80+

70% (95% CI 59-78%

2nd dose, adults 80+

89% (95%CI: 85-93%)

70+ 28-34 days after one dose

61% (95%CI 51-69%)

70+ 28-34 days after one dose

60% (95%CI 41-73%)

70+. >35 days after one dose

73% (95%CI 27-90%)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

https://www.nejm.org/doi/10.1056/NEJMoa2101765

days 14 through 20 after the first dose

57% (95% CI, 50 to 63)

46% (95% CI, 40 to 51)

74% (95% CI, 56 to 86)

62% (95% CI, 39 to 80)

72% (95% CI, 19 to 100)

29% (95% CI, 17 to 39)

days 21 through 27 after first dose

52% (95% CI, 41 to 60)

7 or more days after the second dose

94% (95% CI, 87 to 98)

92% (95% CI, 88 to 95)

87% (95% CI, 55 to 100)

92% (95% CI, 75 to 100)

90% (95% CI, 83 to 94)

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268

>14 days after the second dose

66.7% (57.4%, 74.0%)

"100%" 0 among vacinated vs 15 in control

single dose first 90 days

76%, (95%CI, 59%, 86%),

67% (95%CI 49%, 78%)

(VE 16%, 95% CI - 88%, 62%)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160

28 days after booster?

74.6% [95%CI 41.6-88.9

This was the preprint version, and has slightly different numbers.

28 days after booster?

84% [95% CI 70.7-91.4]

asymptomatic or unknown, sequenced

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0/fulltext

28 days after booster?

70·4% (95% CI 43·6–84·5)

61·7% (36·7 to 76·9)

(28·9%, −77·1 to 71·4)

28 days after booster?

81·5% (67·9–89·4)

77·3% (65·4 to 85·0)

(69·7%, 33·0 to 86·3

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext

two standard doses

62·1% (CI 41·0–75·7)

3·8% (−72·4 to 46·3)

low dose followed by a standard dose

90·0% (67·4–97·0)

58·9% (1·0 to 82·9)

over both groups

70·4% (95·8% CI 54·8–80·6; 30

55·7% (41·1 to 66·7)

27·3% (−17·2 to 54·9)

mRNA-1273: Sponsor Briefing Document Addendum. Vaccines and Related Biological Products Advisory Committee Meeting Presentation

https://www.fda.gov/media/144453/download

just before second dose

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/fulltext

1–14 days after first dose

15–28 days after first dose

not clear how many had had second dose, but presumably it wouldn't have helped yet

Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399

21 days after first dose

72% (95% CI 58-86)

7 days after secodn dose

86% (95% CI 76- 97)

REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963838/AZD1222_Information_for_Healthcare_Professionals_-_22-02-2021.pdf

>65 years old, two doses

51.9% [95%CI: -60.0, 85.5]

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

https://d197for5662m48.cloudfront.net/documents/publicationstatus/58516/preprint_pdf/57fc48596954cc34c20b579f8aca0383.pdf

within 12 weeks of first dose (but after 12 days), before second dose

Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening

https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab229/6167855

either mRNA vaccine

>10 days after first dose

after second dose

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm?s_cid=mm7013e3_w

either mRNA vaccine

>=14 days after first dose but before second dose

80% (95% CI = 59%–90%)

>=14 days after second dose

90% (95% [CI] 68%–97%);

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

https://www.nejm.org/doi/10.1056/NEJMc2101927

either mRNA vaccine

no reported efficacies

Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center

https://www.nejm.org/doi/10.1056/NEJMc2102153

either mRNA vaccine

no reported efficacies

PFIZER AND BIONTECH CONFIRM HIGH EFFICACY AND NO SERIOUS SAFETY CONCERNS THROUGH UP TO SIX MONTHS FOLLOWING SECOND DOSE IN UPDATED TOPLINE ANALYSIS OF LANDMARK COVID-19 VACCINE STUDY

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious

paper not available yet

>7 days after second dose, up to 6 months later

91.3% (CI, 89.0, 93.2)

100% (95% CI, [88.0,100.0]. CDC definition, 95.3% (95% CI, [71.0, 99.9]). FDA definition

92.6% (95% CI, [90.1, 94.5]).

same, South Africa only (a lot of B.1.351)

100% (95% CI, [53.5, 100.0]).

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

https://www.businesswire.com/news/home/20210331005503/en/

paper not available yet

12 to 15 years old

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

https://www.nejm.org/doi/full/10.1056/NEJMoa2102214?query=featured_home

>14 days after second dose

all variants (wild and B.1.351)

21.9% (95% [CI], −49.9 to 59.8)

10.4% (95% CI, −76.8 to 54.8)

most of the variants 39/42 were B.1.351

Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021

https://www.cdc.gov/mmwr/volumes/70/wr/mm7011e3.htm?s_cid=mm7011e3_w

from >14 days after dose 1 through 7 days after dose 2

63% (95% CI 33%–79%)

special population of Skilled nursing facility (SNF) residents

complicated detection procedure, but probably close to "infection"

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

https://www.nejm.org/doi/full/10.1056/NEJMc2103916

serology study 6 months after second dose

Single-dose BNT162b2 vaccine protects aga 1 inst asymptomatic SARS-CoV-2 infection

https://elifesciences.org/articles/68808#content

>=12 days after first dose

COVID-19 Vaccine Ad26.COV2.S VAC31518 (JNJ-78436735) SPONSOR BRIEFING DOCUMENT

https://www.fda.gov/media/146219/download

Johnson and Johnson

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-8/fulltext

>= 7 days after second dose

97·0% (96·7–97·2)

95·3% (95% CI 94·9–95·7

97·2% (96·8–97·5

97·5% (97·1–97·8)

91·5% (90·7–92·2

Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against Acquisitions of SARS-CoV-2 Among Health Care Workers in Long-Term Care Facilities: A Prospective Cohort Study

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3885633

>=14 days after second dose

89% (95% CI 83%, 93%)

health care workers